Related Experiment Video

Updated: Aug 24, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Angiotensin converting enzyme inhibitors for cancer treatment?

Henriette Lindberg1, Dorte Nielsen, Benny V Jensen

  • 1Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark. heli@herlevhosp.kbhamt.dk

Acta Oncologica (Stockholm, Sweden)
|May 28, 2004
PubMed

Insights

Angiotensin converting enzyme inhibitors (ACEi), commonly used for heart and kidney conditions, show potential anti-cancer effects. Studies indicate ACEi can inhibit cancer cell growth, invasion, and metastasis, suggesting a possible role in cancer treatment.

Area of Science:

  • Pharmacology
  • Oncology
  • Cardiovascular Medicine

Background:

  • Angiotensin converting enzyme inhibitors (ACEi) are widely prescribed for cardiovascular and renal diseases.
  • Experimental and epidemiological studies suggest ACEi may possess anti-cancer properties.

Purpose of the Study:

  • To review laboratory investigations and epidemiological studies on the anti-cancer actions of ACEi.
  • To summarize evidence for the potential use of ACEi in cancer treatment.

Main Methods:

  • Review of experimental studies on ACEi effects on cancer cell behavior (proliferation, invasion, angiogenesis).
  • Review of in vivo studies on tumor growth and metastasis inhibition by ACEi.
  • Examination of epidemiological data linking ACEi use to cancer outcomes.

Main Results:

  • ACEi demonstrated inhibition of cancer cell proliferation and invasion in vitro.
  • Tumor growth and metastasis were inhibited in vivo by ACEi.
  • Potential mechanisms include inhibition of matrix metalloprotease, reduced vascular endothelial growth factor, and interference with the renin-angiotensin system.

Conclusions:

  • ACEi exhibit multiple anti-cancer effects demonstrated in laboratory and some epidemiological studies.
  • Further research is warranted to explore the therapeutic potential of ACEi in cancer treatment.

More Related Videos

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring08:45

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...